JP2015501783A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501783A5
JP2015501783A5 JP2014539998A JP2014539998A JP2015501783A5 JP 2015501783 A5 JP2015501783 A5 JP 2015501783A5 JP 2014539998 A JP2014539998 A JP 2014539998A JP 2014539998 A JP2014539998 A JP 2014539998A JP 2015501783 A5 JP2015501783 A5 JP 2015501783A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
following formula
acceptable carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501783A (ja
JP5857136B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/062027 external-priority patent/WO2013066736A1/en
Publication of JP2015501783A publication Critical patent/JP2015501783A/ja
Publication of JP2015501783A5 publication Critical patent/JP2015501783A5/ja
Application granted granted Critical
Publication of JP5857136B2 publication Critical patent/JP5857136B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539998A 2011-11-03 2012-10-26 ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 Expired - Fee Related JP5857136B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161555227P 2011-11-03 2011-11-03
US61/555,227 2011-11-03
US201261672334P 2012-07-17 2012-07-17
US61/672,334 2012-07-17
PCT/US2012/062027 WO2013066736A1 (en) 2011-11-03 2012-10-26 QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015242916A Division JP6114809B2 (ja) 2011-11-03 2015-12-14 ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用

Publications (3)

Publication Number Publication Date
JP2015501783A JP2015501783A (ja) 2015-01-19
JP2015501783A5 true JP2015501783A5 (OSRAM) 2015-12-24
JP5857136B2 JP5857136B2 (ja) 2016-02-10

Family

ID=48192643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014539998A Expired - Fee Related JP5857136B2 (ja) 2011-11-03 2012-10-26 ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用
JP2015242916A Expired - Fee Related JP6114809B2 (ja) 2011-11-03 2015-12-14 ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015242916A Expired - Fee Related JP6114809B2 (ja) 2011-11-03 2015-12-14 ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用

Country Status (16)

Country Link
US (3) US9278960B2 (OSRAM)
EP (1) EP2775841B1 (OSRAM)
JP (2) JP5857136B2 (OSRAM)
KR (1) KR20140088887A (OSRAM)
CN (1) CN104010504B (OSRAM)
AR (1) AR088611A1 (OSRAM)
AU (2) AU2012332895B2 (OSRAM)
CA (1) CA2853923A1 (OSRAM)
CO (1) CO6950474A2 (OSRAM)
IL (1) IL232291A0 (OSRAM)
IN (1) IN2014CN03234A (OSRAM)
MX (1) MX344308B (OSRAM)
MY (1) MY167423A (OSRAM)
RU (1) RU2610262C2 (OSRAM)
TW (1) TWI605040B (OSRAM)
WO (1) WO2013066736A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853923A1 (en) 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2015144001A1 (zh) 2014-03-24 2015-10-01 南京明德新药研发股份有限公司 作为smo抑制剂的喹啉衍生物
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP3174882B1 (en) 2014-08-01 2018-11-07 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
RU2696135C2 (ru) 2014-08-01 2019-07-31 Янссен Фармацевтика Нв 6,7-ДИГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИН-4(5Н)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
JO3601B1 (ar) 2014-08-01 2020-07-05 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
WO2016029454A1 (en) * 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
AU2015357167B2 (en) * 2014-12-03 2020-06-25 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
US10967078B2 (en) 2014-12-03 2021-04-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
WO2016149324A1 (en) * 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
RU2748884C2 (ru) * 2015-07-20 2021-06-01 Джензим Корпорейшн Ингибиторы рецептора колониестимулирующего фактора-1 (csf-1r)
RU2018119344A (ru) 2015-10-26 2019-11-28 Байер Кропсайенс Акциенгезельшафт Конденсированные бициклические гетероциклические производные в качестве средства для борьбы с вредителями
RS60981B1 (sr) 2015-12-18 2020-11-30 Janssen Pharmaceutica Nv Radiooznačeni mglur2/3 pet ligandi
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
PT3519416T (pt) * 2016-09-27 2021-05-13 Merck Sharp & Dohme Derivados de cromano, isocromano e diidroisobenzofurano como moduladores alostericos mglur2-negativos, composições e sua utilização
EP3719023B1 (en) 2017-11-24 2024-10-16 Sumitomo Pharma Co., Ltd. 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF
CN108689957B (zh) * 2018-07-23 2020-07-03 南京药石科技股份有限公司 一种2r/2s-三氟甲基吗啉及其盐酸盐的制备方法和应用
CN113302175A (zh) 2018-11-09 2021-08-24 维瓦斯治疗公司 双环化合物
MX2021012638A (es) 2019-04-16 2022-01-04 Vivace Therapeutics Inc Compuestos biciclicos.
WO2020243049A1 (en) * 2019-05-30 2020-12-03 Merck Sharp & Dohme Corp. Factor xi activation inhibitors
SG11202112539XA (en) 2019-07-01 2021-12-30 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
WO2024112853A1 (en) * 2022-11-24 2024-05-30 Exelixis, Inc. Compounds that inhibit pkmyt1
WO2025101691A1 (en) * 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551831A1 (de) * 1992-01-15 1993-07-21 Hoechst Schering AgrEvo GmbH Verfahren zur Herstellung substituierter 2-Cyanopyridine
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
GB9524137D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU7080198A (en) * 1997-04-25 1998-11-24 Takeda Chemical Industries Ltd. Cell differentiation inducing amide derivatives, their production and use
JPH115772A (ja) * 1997-04-25 1999-01-12 Takeda Chem Ind Ltd アミド誘導体、その製造法および用途
DE60009116T2 (de) * 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
TWI328009B (en) * 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US20060275835A1 (en) 2003-07-11 2006-12-07 Jacobson Marlene A Methods for identifying cell surface receptor protein modulators
US7692017B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
WO2006049968A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
CA2624294A1 (en) * 2005-10-05 2007-04-12 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
AR065093A1 (es) * 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
EP2167469B1 (en) * 2007-06-18 2012-08-15 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CA2853923A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use

Similar Documents

Publication Publication Date Title
JP2015501783A5 (OSRAM)
JP2013525444A5 (OSRAM)
JP2013014622A5 (OSRAM)
JP2014507446A5 (OSRAM)
EP2683382A4 (en) DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY
JP2012255026A5 (OSRAM)
EP2828247A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
EP2819519A4 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
EP2552203A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
JP2016518337A5 (OSRAM)
JP2011518833A5 (OSRAM)
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
EP2911664A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
PL2819663T3 (pl) Nowe podejścia terapeutyczne do leczenia choroby parkinsona
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
EP2579867A4 (en) Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
EP2678009A4 (en) CYSTAMINE ANALOGUE FOR THE TREATMENT OF MORBUS PARKINSON
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
JP2015516419A5 (OSRAM)
EP2676665A4 (en) USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER
JP2012516348A5 (OSRAM)
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EP2900259A4 (en) GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES